European Commission approves Imvanex smallpox vaccine for monkeypox
July 26, 2022
EU approves Imvanex vaccine for monkeypox. Imvanex vaccine label extended to include monkeypox.
Where: World
The Facts
On July 25th, Danish biotechnology company Bavarian Nordic announced that the European Commission had authorized the marketing of their Imvanex smallpox vaccine as protection against monkeypox and disease caused by the vaccinia virus.
The European Medicines Agency recommended the label extension for the Imvanex vaccine last week.
According to Bavarian Nordic, the approval is valid in all member states of the European Union, Iceland, Liechtenstein, and Norway.
The EU approved the Imvanex vaccine for smallpox prevention in 2013. Imvanex is the only vaccine approved for monkeypox prevention in the US and Canada.
The CDC state that the monkeypox and smallpox viruses belong to the same family. While the two diseases have similar symptoms, monkeypox has milder symptoms, is less contagious, and is rarely fatal.
Primary Sources
Direct, authoritative source material on this story.
Reference Articles
Articles Citable has ingested related to this story.
Reference Articles
Articles Citable has ingested related to this story.
Media Coverage
Why did we include this story
Most covered story by the media today
of articles referenced this story
Coverage by Media Outlet
Media outlets covering this story along with their positive or negative sentiment toward this story.
